Source comparison
The Oral vs Injectable Efficacy Gap No One Explains
Oral BPC-157 capsules are marketed at price points 20–35% lower than injectable forms. And they deliver proportionally lower bioavailability. The peptide's molecular weight (1419 Da) and charge distribution make it a poor candidate for gastrointestinal absorpt
This comparison does not assign a generated winner or score.
- Oral BPC-157 capsules are marketed at price points 20–35% lower than injectable forms. And they deliver proportionally lower bioavailability. The peptide's molecular weight (1419 Da) and charge distribution make it a poor candidate for gastrointestinal absorption. When swallowed, BPC-157 encounters gastric acid (pH 1.5–3.5), pepsin, and brush border peptidases. All of which cleave peptide bonds before the compound reaches systemic circulation. Published pharmacokinetic data on oral BPC-157 in rats shows less than 8% bioavailability compared to subcutaneous administration, and no human equivalence studies exist to confirm those numbers hold across species.
- The gastric stability claim marketed for oral BPC-157 is partially true: the compound does resist acid degradation better than many peptides because it's derived from gastric juice proteins. But resistance to degradation isn't the same as absorption. Even if the peptide survives the stomach intact, it still faces enzymatic breakdown in the small intestine and first-pass hepatic metabolism. What reaches the bloodstream is a fraction of the dose on the label. And that fraction hasn't been quantified in humans.
- The financial implication: a 30-day supply of 500mcg oral capsules costs $55–$80. If actual systemic availability is 8% or lower, you're receiving an effective dose of 40mcg or less per capsule. Roughly one-tenth the typical subcutaneous injection dose of 250–500mcg. You're not paying less for equivalent therapy; you're paying moderately less for dramatically reduced therapeutic exposure. Injectable BPC-157, dosed at 250mcg twice daily, costs $85–$120 per month but delivers 12–15× the bioavailable peptide per dollar spent. The math makes oral forms a poor value unless the intended effect is local (gastric mucosal healing), not systemic (tendon or joint repair).